Frequency of chemotherapy Induced Gait Deviations in Breast Cancer Female Survivors

Abstract

Background: Prolonged chemotherapy treatment in breast cancer patients can lead to the development of chemotherapy-induced peripheral neuropathy (CIPN). CIPN is a common adverse effect characterized by symptoms such as gait and balance impairments, as well as weakness in the lower extremities. These symptoms can significantly impact functional abilities and increase the risk of falls among patients. Importantly, these effects may persist even after completion of chemotherapy treatment, leading to long-term challenges in mobility and balance. Objective: To determine chemotherapy induced gait deviations in breast cancer female survivors. Methodology: Descriptive cross-sectional survey was conducted Data from 168 breast cancer survivors were collected from different cancer care hospitals in Lahore. Data collection was done by videotaping patient gait from multiple views and using JAKC Observational Gait Analysis. Results: Results via OGA scale showed deviations in ankle dorsiflexors 114 (67.9%) during mid-stance to terminal stance, inadequate extension of knee 86 (51.2%) during initial contact and inadequate flexion of thigh during initial contact 91(54.2%) and loading response 94 (56.0%). Conclusions: The results revealed gait deviations due to chemotherapy induced peripheral neuropathy in breast cancer survivors which results in slower gait velocity and can predict risk of fall. Keywords: BCS (breast cancer survivors) CIPN (chemotherapy induced peripheral neuropathy), OGA (Observational gait analysis), TUG (timed up and go).

Keywords

• breast cancer survivors
• chemotherapy induced peripheral neuropathy
• observational gait analysis